Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of California, San Francisco
University of Oklahoma
Exelixis
Genmab
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Myeloid Therapeutics
Genentech, Inc.
Deciphera Pharmaceuticals, LLC
Jonsson Comprehensive Cancer Center
Adaptimmune
Avacta Life Sciences Ltd
University of Utah
IDEAYA Biosciences
Memorial Sloan Kettering Cancer Center
Innate Pharma
Pfizer
H. Lee Moffitt Cancer Center and Research Institute
University of Iowa
LG Chem
M.D. Anderson Cancer Center
Astellas Pharma Inc
Jonsson Comprehensive Cancer Center
Incyte Corporation
M.D. Anderson Cancer Center
Pfizer
Tempest Therapeutics
Nurix Therapeutics, Inc.
Pfizer
Exelixis
Jonsson Comprehensive Cancer Center
MacroGenics
Xencor, Inc.
ALX Oncology Inc.
University of Virginia
Incyte Corporation
NextPoint Therapeutics, Inc.
Exelixis
Monopar Therapeutics
Monopar Therapeutics
Kinnate Biopharma
Bayer
Bristol-Myers Squibb
Orion Biotechnology Polska Sp. z o.o.
Eisai Inc.
The Netherlands Cancer Institute
Checkpoint Therapeutics, Inc.
Daiichi Sankyo